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The pharmacokinetics of mezlocillin were studied in 31 children ( For all patients, the mean clearance was 0.21 ± 0.11 liter/h per kg, the mean distribution volume was 0.26 ± 0.13 liter/kg, and the mean elimination half-life was 0.97 ± 0.51 h. Trough concentrations were 23.0 ± 29.9 mg/liter before the dose was administered and 20.4 ± 27.5 mg/liter at the end of the dosing interval. Peak concentrations averaged 245 ± 90.4 mg/liter, and average concentrations for the dosing interval were 83.7 + 40.4 mg/liter. There were no apparent effects of sex, malignancy, age, or dose on either the kinetic parameters or plasma concentrations. Overall, the disposition parameters for mezlocillin in this patient group were comparable to those reported in adults.
Mezlocillin is an acylureido-penicillin effective against a wide range of aerobic and anaerobic gram-negative and gram-positive organisms. Although pharmacokinetic data for mezlocillin are available for adults with normal and/or impaired renal function (1) (2) (3) (4) (5) 8) , similar data for infants or children are scarce (6, 9, 11 Meziocillin administration and specimen collection. Mezlocillin was administered over a 30-min period by an infusion pump at doses ranging from 12.2 to 125 mg/kg every 4 h. Blood samples were obtained for one dosage interval at steady state, usually during day 3 or 4 of therapy. Samples were collected from an indwelling heparin lock immediately before starting the infusion (time zero) and 30, 60, 90, 180, and 240 min after beginning the infusion. The blood was allowed to clot, and the serum was removed and stored at -70°C until assay.
Assay. Serum mezlocillin concentrations were measured in triplicate by the agar diffusion method with Micrococcus luteus ATCC 9341 as the test organism (6) . The assay was sensitive to 1 mg/liter. Standards for comparison were prepared in pooled human plasma. All specimens were obtained at a time when aminoglycoside antibiotics were not being administered.
Pharmacokinetic and statistical analyses. Semi-logarithmic plots of serum mezlocillin concentration versus time over the dosage interval studied showed a log-linear decay from either the peak concentration or that immediately following the peak to the end of the interval. The elimination rate constant (k) was calculated from the slope of that line; all The values for Cl, V, t112, and trough, peak, and average concentrations were examined by using a general linear model technique (11) for effects of sex, malignancy, age, and dose. Because of a correlation between the latter two (r = 0.37; P < 0.05), an interaction term (age with dose) was included in the analysis.
RESULTS
The peak, trough, and average mezlocillin concentrations according to sex are shown in Table 3 . For all patients, trough concentrations averaged 23.0 ± 29.9 mg/liter before the dose was given and 20.4 ± 27.5 mg/liter at the end of the dosing interval. Concentrations peaked at 245 ± 90.4 mg/liter, and the mean concentration for the dosing interval averaged 83.7 ± 40.4 mg/liter. The pharmacokinetic parameters for mezlocillin are detailed in Table 4 . For all patients, clearance averaged 0.21 ± 0.11 liter/h per kg, volume of distribution was 0.26 ± 0.13 liter/kg, and elimination half-life was 0.97 ± 0.51 h.
Statistical analysis failed to demonstrate any significant (P < 0.05) contributions to the variation of any of the concentrations or parameters by sex, malignancy, age, dose, or the interaction of age and dose.
DISCUSSION
With the exception of a preliminary report based on a subgroup of this study (9) , information on the disposition of mezlocillin in children is scant. Trujillo et al. (12) studied 25 children from 4 months to 13.5 years of age who were given mezlocillin at a dose of 50 mg/kg every 4 h. Although pharmacokinetic parameters were not reported, based on their mean peak and trough concentrations, a half-life of 1.3 h may be estimated, which is in reasonable agreement with that in this study (Table 4 ). Rubio and co-workers (10) reported half-lives of 3.73 and 3.84 h in groups of newborn infants weighing 2 kg or less and over 2 kg, respectively; corresponding volumes of distribution were 0.42 and 0.52 liters/kg, approximately twofold higher than that seen in this study (0.26 ± 0.13 liters/kg; Table 4 ). As beta-lactam antibiotics distribute preferentially to extracellular water, which constitutes a higher percentage of total body weight in infants as opposed to children (45 versus 25%) (7), this difference in distribution is to be expected and contributes to the longer half-life. The difference in half-lives may also be related to lower clearances in the newborns due to immature hepatic and renal functions. The disposition parameters for mezlocillin in the pediatric patient group from this study are in reasonable agreement with those reported by Bergan for adults (3) . For a 5.0-g intravenous dose, fairly equivalent to the average dose given in this study, he reported a t1/2 of 1.21 ± 0.45 h, a total clearance of 0.23 liters/h per kg (reported value of 16.96 liters/h normalized to a mean body weight of 73.5 kg), and a volume of distribution of 0.40 liters/kg (calculated from above clearance and the average elimination constant). As can be seen from a comparison with the data in Table 4 for all patients as a group, the disposition parameters in children are similar to those in adults.
Although the clearance and distribution of mezlocillin have been reported to be dose dependent in adults over the range of 13.6 to 68 mg/kg (3) (total doses of 1 to 5 g per mean body weight of 73.5 kg), in this study no dependency on dose was observed in any of the pharmacokinetic parameters or on peak, trough, and mean plasma concentrations over a wider range (12.2 to 125 mg/kg). This difference may be due to the difference in composition of the groups studied, healthy adults as opposed to pediatric oncology patients. Also, as noted before, there was a negative correlation between age and dose, the former ranging from 2 to 19 years, yielding trends toward lower clearances and distribution volumes with an increase in age or a decrease in dose. Consequently, although age and dose were not statistically significant contributors to the variation in the parameters, those factors do affect the data and together may partially explain the lack of dose dependency seen in this study. A clinical and/or bacteriological cure was achieved in 29 of the 31 (94%) children who received mezlocillin and an aminoglycoside antibiotic. The two patients who failed to respond were a child with aplastic anemia who died after a bone marrow transplant and another child with acute myelogenous leukemia who died 3 days after attempted remission. Three children had organisms isolated from blood (two E. coli and one K. oxytoca) which were resistant to mezlocillin. They had a cephalosporin added to their antibiotic regimen.
The disposition parameters for mezlocillin in children from this study are comparable to those reported for adults. Consequently, similar dosage regimens should provide adequate plasma concentrations over time for both groups.
